FOMX
Foamix Pharmaceuticals Ltd.
An Israeli specialty drugmaker built around turning hard-to-deliver medicines into stable foam, Foamix made topical treatments for skin problems like acne and rosacea, including Amzeeq, the first FDA-approved topical foam version of the antibiotic minocycline. Founded in 2003 in Rehovot, Israel, its name blends "foam" and "mix" to reflect its foam delivery science, and in 2020 it merged with Menlo Therapeutics to become VYNE Therapeutics.
CINS: M46135105HealthcareIL1 holder